Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study.
Breast
Carcinoma, Neuroendocrine tumor
Neuroendocrine neoplasms
Prognosis
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
15
05
2023
accepted:
13
07
2023
medline:
18
9
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
ppublish
Résumé
Neuroendocrine neoplasms (NENs) of the breast are rare and not well-studied. NEN are subcategorized as well-differentiated neuroendocrine tumor (NET) and poorly differentiated neuroendocrine carcinoma (NEC). The objectives of the current study were to review the clinicopathologic features of NENs, therapeutic efficacy of current systemic therapy and clinical outcomes of NEN of the breast. Between 2004 and 2015, 420 NET, 205 NEC, 146 Adenocarcinoma with NE differentiation (ACNED) and 1,479,520 of invasive carcinoma, not otherwise specified (IC-NOS) of the breast were identified in the National Caner Database. Overall survival was compared among groups using Kaplan-Meier method and Log-rank test. Multivariate analyses were performed to identify prognostic factors. After adjusting for other prognostic factors, both NET and NEC of the breast showed significantly worse OS than IC-NOS (HR (95% CI) = 1.41 (1.17, 1.72), p = 0.005 and HR (95% CI) = 2.11 (1.67, 2.67), p < 0.001, respectively). Both NET and NEC benefited from endocrine therapy if the tumors were hormonal receptor positive (median OS for treated with vs without: 125 vs 57 months in NET, not reached vs 29 months in NEC). NEC also benefited from chemotherapy (median OS for treated with vs without: 42 vs 34 months), but not NET. NEN is a unique pathologic and clinical entity, which has worse clinical outcome compared to IC-NOS of the breast. Current therapeutics used in the treatment of IC-NOS improve, but do not fully mitigate, the poorer prognosis of NEN patients. More effective therapy for patients with this unique tumor type are needed.
Identifiants
pubmed: 37566192
doi: 10.1007/s10549-023-07052-5
pii: 10.1007/s10549-023-07052-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-32Subventions
Organisme : NCI NIH HHS
ID : P30CA16672
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA269696
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA16672
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA269696
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ellis IOCC, Schnitt SJ, Sasco AJ, Sastre-Garau X et al (2003) Neuroendocrine tumours. In: Tavassoli FA, Devilee P (eds) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs, vol 2003. IARC Press, Lyon, France, pp 32–34
Bussolati G, Badve S (2012) Carcinoma with neuroendocrine features. In: Lakhani SA, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds) WHO Classification of Tumours, 4th Edition: Breast Tumours. IARC Press, Lyon, France, pp 62–63
Rakha EA, JS Reis-Filho, Sasano H, Wu Y. (2019) Neuroendocrine neoplasms. In: WHO classification of tumors editorial board (ed) WHO Classification of Tumours, 5th Edition: Breast Tumours. IARC Press, Lyon, France, pp 155–161
Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Kloppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31(12):1770–1786. https://doi.org/10.1038/s41379-018-0110-y
doi: 10.1038/s41379-018-0110-y
pubmed: 30140036
pmcid: 6265262
American College of Surgeons. About the National Cancer Database. Accessed June 2019 https://www.facs.org/quality-programs/cance r/ncdb/about
Kaplan EL, Meier P (1958) Nonparametric estimator from incomplete observations. J Am Stat Assoc 53:457–481
doi: 10.1080/01621459.1958.10501452
Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 60:163–170
Cox RD (1972) Regression models and life-tables. J Royal Stat Soc: Series B (Methodological) 34:187
Wei B, Ding T, Xing Y, Wei W, Tian Z, Tang F, Abraham S, Nayeemuddin K, Hunt K, Wu Y (2010) Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer 116(19):4463–4473. https://doi.org/10.1002/cncr.25352
doi: 10.1002/cncr.25352
pubmed: 20572042
Bogina G, Munari E, Brunelli M, Bortesi L, Marconi M, Sommaggio M et al (2016) Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. Histopathology 68(3):422–432. https://doi.org/10.1111/his.12766
doi: 10.1111/his.12766
pubmed: 26114478
Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann L, Bonneau C et al (2018) Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Mod Pathol 31(1):68–82. https://doi.org/10.1038/modpathol.2017.107
doi: 10.1038/modpathol.2017.107
pubmed: 28884749
Zhang Y, Chen Z, Bao Y, Du Z, Li Q, Zhao Y et al (2013) Invasive neuroendocrine carcinoma of the breast: a prognostic research of 107 Chinese patients. Neoplasma 60:215–222
doi: 10.4149/neo_2013_029
pubmed: 23259792
Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D (2003) Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol 34:1001–1008
doi: 10.1053/S0046-8177(03)00411-8
pubmed: 14608533
Rovera F, Masciocchi P, Coglitore A, La Rosa S, Dionigi G, Marelli M et al (2008) Neuroendocrine carcinoma of the breast. Int J Surg. https://doi.org/10.1016/j.ijsu.2008.12.007
doi: 10.1016/j.ijsu.2008.12.007
pubmed: 19269908
Martinez EO, Jorns JM, Kong AL, Kijas J, Lee WYHuang CC, et al (2022) Primary breast neuroendocrine tumors: an analysis of the national cancer database. Ann Surg Oncol 29:6339–6346
doi: 10.1245/s10434-022-12123-w
pubmed: 35789311
Cloyd JM, Yang RL, Allison KH, Norton JA, Hernandez-Boussard T, Wapnir IL (2014) Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. Breast Cancer Res Treat 148(3):637–644. https://doi.org/10.1007/s10549-014-3207-0
doi: 10.1007/s10549-014-3207-0
pubmed: 25399232
Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y (2014) Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer 14:147. https://doi.org/10.1186/1471-2407-14-147
doi: 10.1186/1471-2407-14-147
pubmed: 24589259
pmcid: 3974013
Yang L, Roy M, Lin H, Shen Y, Albarracin CT, Huo L et al (2021) Validation of prognostic significance of the proposed uniform classification framework in neuroendoccrine neoplasms of the breast. Breast Cancer Res Treat 86(2):403–415. https://doi.org/10.1007/s10549-021-06099-6
doi: 10.1007/s10549-021-06099-6
Miremadi A, Pinder SE, Lee AH, Bell JA, Paish EC, Wencyk P et al (2002) Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology 40:215–222
doi: 10.1046/j.1365-2559.2002.01336.x
pubmed: 11895486
van Krimpen C, Elferink A, Broodman CA, Hop WC, Pronk A, Menke M (2004) The prognostic influence of neuroendocrine differentiation in breast cancer: results of a long-term follow-up study. Breast 13:329–333
doi: 10.1016/j.breast.2003.11.008
pubmed: 15325669
Chai Y, Liu M, Li Z, Chen Y, Qi F, Li Q et al (2022) Retrospective literature review of primary neuroendocrine neoplasms of the breast (BNEN) in 209 Chinese patients: Treatment and prognostic factor analysis. Breast 62:93–102
doi: 10.1016/j.breast.2022.01.013
pubmed: 35134665
pmcid: 8844750